Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 9/20 | 0.40 |
| ▸ | MMP8 | P22894 | 4/20 | 0.40 |
| ▸ | MMP3 | P08254 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833963 | 0.92 | ALDH1A1 (0.42) | TRPA1MMP8MMP3LMNA | |
| SCHEMBL4840572 | 0.92 | LMNA (0.41) | TRPA1MMP8MMP3LMNARORC | |
| SCHEMBL4844332 | 0.92 | MEN1 (0.40) | TRPA1MMP8MMP3LMNARORC | |
| SCHEMBL4841593 | 0.91 | TRPA1 (0.40) | TRPA1MMP8MMP3LMNARORC | |
| SCHEMBL4904311 | 0.91 | TRPA1 (0.43) | TRPA1LMNA | |
| SCHEMBL4833948 | 0.89 | MMP8 (0.43) | TRPA1MMP8MMP3PTGER3 | |
| SCHEMBL4833927 | 0.86 | TRPA1 (0.41) | TRPA1LMNA | |
| SCHEMBL4832648 | 0.85 | SCN9A (0.48) | TRPA1MMP8MMP3LMNAPTGER3 | |
| SCHEMBL4841061 | 0.85 | ATM (0.45) | TRPA1LMNAPTGER3ATM | |
| SCHEMBL4842502 | 0.84 | TRPA1 (0.43) | TRPA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2268270-A2 | IMPROVED FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS | Abbott Products GmbH (DE) | 2011-01-05 | — | — | EP | claimed |
| WO-2009130204-A2 | IMPROVED FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-10-29 | — | — | WO | claimed |
| US-20090263479-A1 | FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS | SOLVAY PHAMACEUTICALS GMBH | 2009-10-22 | — | — | US | claimed |
| EP-2268270-A2 | IMPROVED FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS | Abbott Products GmbH (DE) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009130204-A2 | IMPROVED FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090263479-A1 | FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS | SOLVAY PHAMACEUTICALS GMBH | 2009-10-22 | — | — | US | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | TRPA1 368/4885MMP8 3968/4885MMP3 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.